Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
11 janv. 2017 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that the rintatolimod European early access program (EAP) designed...
Independence Blue Cross announces new Employee Assistance Program for employers with 100+ employees
07 déc. 2015 11h00 HE
|
Independence Blue Cross
PHILADELPHIA, PA., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Independence Blue Cross (Independence) announces Personal Life Management(SM) — a new Employee Assistance Program (EAP) providing...
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
15 févr. 2015 18h33 HE
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Feb. 15, 2015 (GLOBE NEWSWIRE) -- Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for...